4036-25: Mind and Metabolism in Harmony: Addressing the Metabolic Side Effects of Second-Generation Antipsychotics with Topamax, Metformin, and GLP-1 Receptor Agonists 

This dynamic presentation explores the cardiometabolic risks associated with second-generation antipsychotic medications. It highlights the efficacy of topiramate, metformin, and GLP-1 receptor agonists in managing these risks, including weight loss, improved BMI, enhanced glycemic and lipid profiles, increased medication compliance, and improved self-esteem in patients with psychotic disorders.

Presenters:  Tiffany Pressley, DNP, APRN, PMHNP-BC, PMH-BC, CNE, CMSRN; Nina Russell, DNP, FNP-C, MSN-Ed, APRN

Disclosures:  The APNA planners and faculty, with the exception of those listed below, have no relevant financial relationships to disclose. All relevant financial relationships listed for these individuals have been mitigated. Off-label uses will not be discussed during this presentation.

Tiffany Pressley, DNP, APRN, PMHNP-BC, PMH-BC, CNE, CMSRN is the CEO of BIA Healthcare. The presentation content is not related to the business lines of BIA Healthcare.

Session Length:  30 minutes

Target Audience:  RN, APRN

Learning Outcome:
Upon completion of this presentation, the participant will be able to:

• Understand cardiometabolic risks associated with SG2-antipsychotic medications. 

Key Takeaway(s): 

• Topiramate, metformin, and GLP-1 receptor agonists are effective in managing SGA risks, including weight loss, improved BMI, and increased medication compliance.

Keywords:  Pharmacology

Nursing Continuing Professional Development:
0.5 pharmacology contact hours.  * In order to receive contact hours, you must: Listen to the entire presentation, complete the reflection activity, evaluation, and honor statement before the expiration date. Once all steps are successfully completed, a certificate will be generated online and available for you to print immediately. Contact hours cannot be awarded unless all required components are completed. 

The American Psychiatric Nurses Association is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Release Date:  December 8, 2025
Access to this course will end:  December 1, 2027

*For an uninterrupted learning experience, please download and use Google Chrome, Mozilla Firefox, Microsoft Edge, Safari, etc. If you continue to experience issues, you may need to update your browser.